Bristol-Myers Squibb Company BMY announced today that the waiting
period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as
amended for its tender offer for Inhibitex, Inc. INHX has
expired.
Bristol-Myers Squibb initiated on January 13, 2012, through its wholly-owned
subsidiary Inta Acquisition Corporation, a cash tender offer to purchase all
outstanding shares of common stock of Inhibitex for $26.00 per share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in